Latest News

(UroToday.com) There has been a proliferation in treatment options for patients with metastatic castration resistant prostate cancer (mCRPC) in the last 10 years. While there are many available treatment options, to date, we have been unable to widely operationalize rationale treatment selection in this disease space. In many cases, oncologic outcomes are similar between treatment options. […]

(UroToday.com) Following two presentations from Dr. D’Amico and Dr. McBride looking at docetaxel and abiraterone acetate, respectively, as treatment intensification for patients treated with radiotherapy and androgen deprivation therapy for patients with locally advanced prostate cancer, Dr. Vapiwala provided a discussant overview of these data and helped to contextualize how we may apply them to our […]

(UroToday.com) Current standard-of-care therapies for metastatic castration-resistant prostate cancer (mCRPC) include taxanes, novel hormonal therapies that target the androgen receptor or androgen signaling, such as enzalutamide or abiraterone, sipuleucel-T, or targeted alpha therapies. Approximately 23-27% of men with mCRPC harbor somatic and/or germline deletions and/or deleterious alterations in DNA damage response genes involved in homologous recombination […]

(UroToday.com) There has been a proliferation in treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC) in the last 10 years. While the most commonly utilized approaches in prostate cancer are cytotoxic chemotherapy or target the androgen-axis, recently, theranostic treatment with the PSMA-targeting radioligand therapy Lu-177 PSMA has demonstrated promising activity among pre-treated individuals with […]

(UroToday.com) While there have been transformational changes in first-line therapy for patients with advanced renal cell carcinoma (RCC) in the past three years, these studies have focused on patients with clear cell histology. As a result, there have been little direct data to guide care for patients with non-clear cell histologies and we have had to […]

(UroToday.com) Radium-223 is a bone-targeted alpha therapy and has been shown to prolong survival in patients with symptomatic metastatic castration-resistant prostate cancer (mCRPC) to the bone.1 Docetaxel targets microtubule trafficking and has been shown to improve survival in both the mCRPC and metastatic hormone-sensitive settings. It has previously been hypothesized that simultaneously targeting the tumor and […]

(UroToday.com) Men with mCRPC often receive sequential NAH (abiraterone and enzalutamide) despite reported cross-resistance, indicating a need for further life-prolonging options for progressive disease after prior NAH. Radium-223 is a targeted alpha therapy approved for mCRPC with symptomatic bone metastases based on the phase 3 ALSYMPCA study, in which it demonstrated significantly increased overall survival (OS), […]

(UroToday.com) There have been transformational changes in first-line therapy for patients with advanced renal cell carcinoma (RCC) in the past three years. Foremost among these is the move from monotherapy to combination approaches. While CheckMate 214 first brought combination therapy with dual checkpoint inhibition (nivolumab and ipilimumab) to the forefront, subsequent studies have examined combinations […]

(UroToday.com) At the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting, during the session on sequencing therapies in advanced kidney cancer in the contemporary era, Dr. Eric Singer presenting on the role of surgery and radiation therapy in the integration of multimodality treatment for advanced kidney cancer.

(UroToday.com) There have been transformational changes in first-line therapy for patients with metastatic renal cell carcinoma (RCC) in the past three years. Foremost among these is the move from monotherapy to combination approaches. While CheckMate 214 first brought combination therapy with dual checkpoint inhibition (nivolumab and ipilimumab) to the forefront, subsequent studies have examined combinations of […]